No Data
Hua Ling Pharmaceutical (02552.HK) has completed two drug studies.
Huale Pharmaceutical (02552.HK) announced in a press release that it had successfully completed the clinical study of the second-generation glucokinase activator (GKA) conducted in the usa at the Ninth China Pharma Innovation and Investment Conference earlier. The related clinical study is designed for once-daily oral administration, aiming to extend the drug's action time in the body through sustained-release technology, improve patient compliance, and prolong the stimulation of GLP-1 secretion in the intestine. In addition, Huale Pharmaceutical also announced on the same day that it had successfully completed the SENSITIZE study conducted in collaboration with the Chinese University of Hong Kong, which aims to improve β-cell function with multiple doses of rosiglitazone.
Express News | China's Leading Pharmaceutical announces the completion of two clinical studies.
Hualing Pharmaceutical announced the successful completion of Phase I clinical trials for its second-generation glucokinase activator conducted in the usa.
Shanghai November 30, 2024 / USA / -- china meheco group ("the Company", Stock Code: 2552.HK) announced today at the Ninth China BioMed Innovation and Investment Conference (CBIIC) that it has successfully completed the phase Ia clinical trial of the second-generation Glucose Kinase Activator (GKA) conducted in the United States. The phase Ia clinical trial of the second-generation GKA (HM-002-1005) was
Hualing Pharmaceuticals announced the successful completion of the SENSITIZE study conducted in Hong Kong, China.
Shanghai, November 30, 2024 /PR Newswire/ -- Hua Ling Pharmaceuticals ("the Company", Hong Kong Stock Exchange stock code: 2552.HK) today announced at the 9th China BioMed Innovation and Investment Conference (hereinafter referred to as CBIIC) that the Company has successfully completed the SENSITIZE study in collaboration with Professor Juliana Chan's team from the Chinese University of Hong Kong, which studies how Dapagliflozin improves β-cell glucose.
This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.
Many innovative drugs stocks in Hong Kong suddenly soared!
On the morning of November 25, the hang seng index fell slightly, while the Hong Kong stock market's biomedical sector performed well. Notably, several biomedical companies saw their stock prices rise significantly due to recent news of major collaboration advancements.
No Data
